Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Intercept Pharmaceut (ICPT) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,473,460
  • Shares Outstanding, K 24,730
  • Annual Sales, $ 2,780 K
  • Annual Income, $ -226,430 K
  • 36-Month Beta -2.12
  • Price/Sales 889.09
  • Price/Book 5.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.35 +6.05%
on 11/08/16
118.74 -13.05%
on 11/10/16
+5.40 (+5.52%)
since 11/04/16
3-Month
96.63 +6.84%
on 11/04/16
172.95 -40.31%
on 09/21/16
-47.50 (-31.51%)
since 09/02/16
52-Week
89.76 +15.02%
on 02/11/16
177.93 -41.98%
on 08/01/16
-52.00 (-33.50%)
since 12/04/15

Most Recent Stories

More News
Intercept Presents New Data at AASLD Examining the Effects of Ocaliva(R) (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,...

Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss

Intercept (ICPT) reported a narrower-than-expected loss of $3.59 in the third-quarter of 2016.

Intercept (ICPT) Reports Narrower-Than-Expected Q3 Loss

Intercept (ICPT) reported a narrower-than-expected loss of $3.59 in the third-quarter of 2016.

Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

-- Net Ocaliva (obeticholic acid or OCA) 3Q sales of $4.7 million

Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX

Three more companies from the healthcare sector are set to report their third-quarter results on Nov 3. Let's see how things are shaping up for their respective announcements.

Intercept (ICPT) Q3 Earnings Preview: What's in the Cards?

Intercept (ICPT) is scheduled to report third-quarter 2016 results on Nov 3 before market opens.

Intercept Announces Ocaliva(R) (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases,...

Intercept to Report Third Quarter 2016 Financial Results on November 3

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced...

Vertex (VRTX) Q3 Earnings: What's in Store for the Stock?

Biotech company Vertex Pharmaceuticals (VRTX) will be reporting third-quarter 2016 results on Oct 25, after the market closes.

Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC

Intercept's (ICPT) Ocaliva received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Support & Resistance

2nd Resistance Point 109.52
1st Resistance Point 106.38
Last Price 103.24
1st Support Level 100.30
2nd Support Level 97.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.